Clinical Trial Update: Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels [Phase 2]

View source ↗

Summary

Phase 2 trial results reported on the efficacy and safety of JTT-302 in subjects with low HDL-C levels (dyslipidemia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• JTT-302

Snippet

Sponsor: Akros Pharma Inc. | Conditions: Dyslipidemia | Phase 2 | Status: COMPLETED